Bioaffinity Technologies, INC Form 4 insider transactions

Xavier Trinidad Reveles, COO of bioAffinity Technologies, reports acquisition and disposal of common stock on January 10, 2025.

Executive Chairman Steven Girgenti reports acquisition and disposal of bioAffinity Technologies stock, including a grant of restricted shares and shares held by a trust.

Maria Zannes, President & CEO of bioAffinity Technologies, reports the acquisition of 37,037 shares of restricted common stock.

James Michael Edwards, VP and CFO of bioAffinity Technologies, reports the acquisition of 6,172 shares of common stock through a grant and the resulting adjusted beneficial ownership.

Timothy P. Zannes, Secretary, EVP, and General Counsel of bioAffinity Technologies, acquired 8,641 shares of common stock through a grant, increasing his holdings to 54,765 shares.

James Michael Edwards, VP and CFO of bioAffinity Technologies, acquired 100,000 shares of common stock on November 5, 2024, through a grant of restricted shares.

Director Stuart Diamond reports acquiring 33,784 shares of bioAffinity Technologies common stock and disposing of 99,088 shares on July 1, 2024.

Steven Girgenti, Executive Chairman of bioAffinity Technologies, reports acquisition and disposal of common stock, including a grant of restricted shares.

Robert A. Anderson, a director at bioAffinity Technologies, acquired 33,784 shares of common stock and disposed of 163,936 shares on July 1, 2024.

Director Roby Joyce reports acquiring 33,784 shares of BioAffinity Technologies and disposing of 66,615 shares, while also holding shares indirectly through The Joyce Living Trust.

Director Jamie Platt reports acquisition of 33,784 shares and disposal of shares in bioAffinity Technologies, Inc.

Maria Zannes, CEO of bioAffinity Technologies, acquired 33,784 shares of restricted common stock on July 1, 2024, as part of a grant that vests monthly over 12 months.

Gary Rubin, a director and 10% owner of bioAffinity Technologies, reported the acquisition of restricted shares and holdings through the Harvey Sandler Revocable Trust.

Director Peter Knight received a grant of restricted shares in BioAffinity Technologies, according to a recent SEC filing.

Gary Rubin, a director and 10% owner of bioAffinity Technologies, acquired 8,296 shares of common stock on June 12, 2024.

Director Stuart Diamond received a grant of 8,296 restricted shares of bioAffinity Technologies, Inc. common stock that vest immediately.

Steven Girgenti, Executive Chairman of bioAffinity Technologies, reports acquiring shares of common stock and holding shares indirectly through a trust.

Maria Zannes, CEO of bioAffinity Technologies, received a grant of 8,296 shares of common stock on June 12, 2024.

Director Roby Joyce acquired 8,296 shares of BioAffinity Technologies common stock on June 12, 2024, through a grant of restricted shares that vest immediately.

Director Jamie Platt of bioAffinity Technologies reports acquiring and disposing of common stock on June 12, 2024.

Director Peter Knight acquired 8,296 shares of BioAffinity Technologies common stock on June 12, 2024, through a grant of restricted shares that vest immediately.

Robert A. Anderson, a director at bioAffinity Technologies, acquired 8,296 shares of common stock through a grant that vested immediately.

Maria Zannes, CEO of bioAffinity Technologies, exercised stock options and disposed of shares to cover the exercise price, according to a recent SEC filing.

Timothy P. Zannes, Secretary, EVP, and General Counsel of bioAffinity Technologies, exercised stock options and sold shares to cover the exercise price.

Director Steven Girgenti exercised stock options and disposed of shares to cover the exercise price, resulting in a net change in his beneficial ownership of BioAffinity Technologies stock.

Steven Girgenti, Executive Chairman of bioAffinity Technologies, reports acquiring shares and holding them directly and indirectly through a trust.

Robert A. Anderson, a director at bioAffinity Technologies, exercised stock options and disposed of 64,848 common stock shares on February 26, 2024.